Cell Death: Mechanisms and Potential Targets in Breast Cancer Therapy

J Qian, Linna Zhao, Ling Xu, Jin Zhao, Yongxu Tang, Min Yu, Jie Lin, Lei Ding, Qinghua CuiInternational Journal of Molecular Sciences 2024 · DOI

TL;DR

This review explores the diverse mechanisms of programmed cell death (PCD) – including autophagy, apoptosis, pyroptosis, necroptosis, ferroptosis, and cuproptosis – and their intricate interplay in breast cancer (BC). By understanding these complex pathways and their dysregulation in BC, researchers aim to identify novel therapeutic targets that can overcome treatment resistance and improve patient outcomes.

What Problem Does This Paper Address?

Breast cancer (BC) remains a significant global health challenge, characterized by its molecular heterogeneity, leading to diverse subtypes, variable prognoses, and often unpredictable responses to current therapies. A major hurdle in effective BC treatment is the complex interplay of various cell death pathways. While many therapeutic strategies focus on a single mode of cell death, this approach often overlooks the dynamic interactions and transitions between different death mechanisms, contributing to drug resistance and treatment failure. This paper addresses the critical need to understand the multifaceted nature of cell death in BC, including newly discovered pathways like ferroptosis and cuproptosis, to unlock more effective and targeted therapeutic strategies.

Methods

This paper is a comprehensive review, not an experimental study. Therefore, it does not present novel methods or algorithms. Instead, it synthesizes and analyzes existing research from a vast body of literature. The authors systematically review and discuss:

  • Mechanisms of various cell death types: Detailed descriptions of the molecular triggers, signaling cascades, and key genes involved in autophagy, apoptosis, pyroptosis, necroptosis, ferroptosis, and cuproptosis.
  • Dysregulation of these pathways in Breast Cancer: How these cell death mechanisms are altered in BC development, progression, and in response to therapy.
  • Therapeutic potential: How targeting these specific cell death pathways or their regulators can be leveraged for BC treatment.
  • Crosstalk between cell death pathways: The complex interactions and interdependencies between different modes of cell death, particularly in the context of BC and drug resistance.

Datasets

Not discussed in the paper. This is a review article that synthesizes existing research.

Key Insights and Ideas

  • Beyond Apoptosis: While apoptosis has been the traditional focus of cancer therapy, the review highlights that other cell death pathways, like pyroptosis, necroptosis, ferroptosis, and cuproptosis, are equally crucial and offer new therapeutic avenues.
  • PANoptosis: A Unified Framework: The concept of PANoptosis, which integrates apoptosis, pyroptosis, and necroptosis, suggests a more holistic view of cell death regulation and offers a powerful strategy for cancer inhibition.
  • Metal Ions as Key Regulators: The emerging roles of iron (in ferroptosis) and copper (in cuproptosis) as critical regulators of cell death pathways are emphasized, opening doors for metal-targeted therapies.
  • Crosstalk is Crucial: The intricate "crosstalk" between different cell death mechanisms is not just a theoretical concept but a critical factor influencing treatment response and drug resistance in BC. Understanding these interactions is key to developing effective combination therapies.
  • Heterogeneity is a Challenge and an Opportunity: The molecular heterogeneity of BC, which complicates treatment, also means that different cell death pathways might be more relevant for specific BC subtypes, allowing for personalized therapeutic approaches.

Key Results

As a review article, this paper does not present quantitative experimental results. Instead, its key "results" are the synthesized insights and comprehensive overview of the current understanding of cell death mechanisms in breast cancer. These include:

  • Detailed characterization of six major cell death pathways: Autophagy, apoptosis, pyroptosis, necroptosis, ferroptosis, and cuproptosis are described with their molecular players and triggers.
  • Identification of dysregulated genes and pathways in BC: The review points to specific genes and signaling cascades within each cell death pathway that are frequently altered in BC, suggesting them as potential therapeutic targets.
  • Evidence for the therapeutic potential of targeting cell death: The paper compiles numerous studies demonstrating how manipulating these pathways can inhibit BC growth, enhance drug sensitivity, and overcome resistance.
  • Highlighting the importance of PANoptosis and metal-ion-mediated cell death: These newer concepts are presented as promising areas for future research and therapeutic development.

Limitations and Future Work

  • Complexity of Crosstalk: The authors acknowledge the immense complexity of the crosstalk between various cell death pathways. While they outline some interactions, a complete understanding of these intricate networks is still evolving. Future work should focus on further elucidating these cross-regulatory mechanisms.
  • Therapeutic Translation: While many potential targets are identified, translating these findings into effective clinical treatments for BC remains a significant challenge. Further research is needed to develop safe and potent drugs that can specifically modulate these cell death pathways in vivo.
  • Subtype-Specific Therapies: The review implicitly suggests that different BC subtypes might rely on different cell death mechanisms. Future research should aim to identify which cell death pathways are most critical for specific BC subtypes to enable more personalized and effective therapeutic strategies.
  • In Vivo Validation: Many of the discussed therapeutic strategies are based on in vitro studies or preclinical models. More extensive in vivo validation and clinical trials are necessary to confirm their efficacy and safety in human patients.
  • Novel Drug Development: The authors emphasize the need for developing novel targeted therapeutics that can exploit or inhibit specific cell death pathways, particularly those that are currently under-represented in BC treatment strategies.

Summary updated

Abstract

Breast cancer (BC) has become the most life-threatening cancer to women worldwide, with multiple subtypes, poor prognosis, and rising mortality. The molecular heterogeneity of BC limits the efficacy and represents challenges for existing therapies, mainly due to the unpredictable clinical response, the reason for which probably lies in the interactions and alterations of diverse cell death pathways. However, most studies and drugs have focused on a single type of cell death, while the therapeutic opportunities related to other cell death pathways are often neglected. Therefore, it is critical to identify the predominant type of cell death, the transition to different cell death patterns during treatment, and the underlying regulatory mechanisms in BC. In this review, we summarize the characteristics of various forms of cell death, including PANoptosis (pyroptosis, apoptosis, necroptosis), autophagy, ferroptosis, and cuproptosis, and discuss their triggers and signaling cascades in BC, which may provide a reference for future pathogenesis research and allow for the development of novel targeted therapeutics in BC.
BibTeX
@article{qian2024cell,
  author = {J Qian and Linna Zhao and Ling Xu and Jin Zhao and Yongxu Tang and Min Yu and Jie Lin and Lei Ding and Qinghua Cui},
  title = {{Cell Death: Mechanisms and Potential Targets in Breast Cancer Therapy}},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179703},
}
Figure